SCHEMBL2014684

SCHEMBL2014684

CC(=O)c1cc(Cl)c2cccnc2c1N1CCC(Oc2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP3A4 P08684 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HRH1 P35367 2/20 0.43
CCR3 P51677 2/20 0.43
KCNH2 Q12809 2/20 0.43
GPR6 P46095 1/20 0.41
ALOX12 P18054 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
SCN9A Q15858 1/20 0.40
ACACB O00763 1/20 0.40
SLC40A1 Q9NP59 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163888 0.88 ALDH1A1 (0.46) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2163944 0.85 ALDH1A1 (0.43) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2164614 0.84 RAB9A (0.46) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2164144 0.84 ALDH1A1 (0.45) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL12631390 0.83 ALOX12 (0.45) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2164381 0.83 NPSR1 (0.42) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2163557 0.82 MELK (0.43) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL12631360 0.82 ALDH1A1 (0.50) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2163584 0.82 IRAK4 (0.44) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2
SCHEMBL2012673 0.81 NPC1 (0.42) ALDH1A1CYP2C9CYP3A4MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 ALDH1A1 3722/4885CYP2C9 655/4885CYP3A4 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.